Researchers Find Potential New Treatment Target for Deadly Brain Cancer
A team of researchers has found a key player in brain tumor formation that may lead to new therapies for a deadly and incurable cancer. The study is the first to show that a protein called OSMR (oncostatin m receptor) is required for glioblastoma tumors to form. [Press release from the Ottawa Hospital Research Institute discussing online prepublication in Nature Neuroscience] Press Release|Abstract
Biomarker-Specific Conjugated Nanopolyplexes for the Active Coloring of Stem-Like Cancer Cells
Stem-like cancer cells possess intrinsic features and their CD44 regulate redox balance in cancer cells to survive under stress conditions. Thus, researchers have fabricated biomarker-specific conjugated polyplexes using CD44-targetable hyaluronic acid and redox-sensible polyaniline based on a nanoemulsion method. [Nanotechnology] Abstract
A Convenient and Effective Strategy for the Enrichment of Tumor-Initiating Cell Properties in Prostate Cancer Cells
For prostate cancer (PrCa) tumor-initiating cells (PrTICs) enrichment, scientists induced cancer stem cell (CSC) properties in PrCa cells by transducing three defined factors (OCT3/4, SOX2, and KLF4), followed by culture with conventional serum-containing medium. The CSC properties in the transduced cells were evaluated by proliferation, cell cycle, side population assay, drug sensitivity technology, in vivo tumorigenicity, and molecular marker analysis of PrCSCs compared with parental cells and spheroids. [Tumor Biol] Abstract
To Wake Up Cancer Stem Cells, or to Let Them Sleep, that Is the Question
The reviewers address two opposite approaches to the therapeutic targeting of cancer stem cells (CSCs)-wake-up and hibernation therapies that either promote or prevent the entry of CSCs into the cell cycle, respectively, and they discuss the potential advantages and risks of each strategy. [Cancer Sci] Full Article
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
INDUSTRY NEWS
Celsion Corporation Announces Enrollment of First Patient in the OPTIMA Study in China
Celsion Corporation announced that the first patient in China has been enrolled in its ongoing global Phase III OPTIMA Study evaluating ThermoDox®, Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation to treat newly diagnosed patients with primary liver cancer. [Celsion Corporation] Press Release
Bristol-Myers Squibb’s Opdivo® (Nivolumab) Receives Breakthrough Therapy Designation
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Opdivo for the potential indication of recurrent or metastatic squamous cell carcinoma of the head and neck after platinum based therapy. [Bristol-Myers Squibb Company] Press Release
